NEW YORK / May 02, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Bank of America Securities 2023 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 9, 2023. Adam Lenkowsky, Executive Vice President, Chief Commercialization Officer, will answer questions about the company at 8:40 a.m. PT/11:40 a.m. ET.
Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com. An archived edition of the session will be available later that day.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$57.33 |
| Daily Change: | 1.03 1.83 |
| Daily Volume: | 39,505,640 |
| Market Cap: | US$116.380B |
December 09, 2024 November 19, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
